Fetal antigens as tumor growth enhancing factors in Yoshida's tumor rats

Boll Soc Ital Biol Sper. 1990 Nov;66(11):1105-12.

Abstract

Malignant neoplastic cells have been shown to have some antigenic features identical to those of embryonic cells. Since several antigens are likely to be shared by both embryonic cells and neoplastic tissue, we tried to understand the meaning of the appearance of such antigens and the type of effect that the immunization with embryonic antigens would have on the survival of Yoshida's tumor rats. Wistar rats were immunized with fetal antigens by fetal cells (1.5 x 10(6)) suspended in 0.5 ml of Hanks solution plus an equal volume of Freund adjuvant, were injected in hind footpads, i.p. and i.m., respectively, for active immunization. Rabbit antigen sera were used for passive immunization. All animals presented ascites and tumor growth. Animals immunized by means of fetal cell antigens showed a mean survival rate after neoplastic transplant of 14 days. Animals that received rabbit immune serum showed a mean survival rate after neoplastic transplant of 17 days. The immunization by means of fetal antigens elicited a scanty effect on the survival of Yoshida's tumor transplanted rats. It can be concluded that antibodies, which are able to cross react with neoplastic cells, do not have cytotoxic effect and do not interfere with the survival of the neoplastic transplanted animals. Therefore, fetal antigens are likely able to carry out an immunosuppressive action. The fact that they appear on neoplastic cells could be seen as a metabolic modification effect or as a growth enhancing factor.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antibodies, Neoplasm / immunology
  • Antigens, Neoplasm / physiology*
  • Fetus / immunology*
  • Graft Rejection
  • Immune Tolerance
  • Immunization
  • Male
  • Neoplasm Transplantation
  • Rabbits
  • Rats
  • Rats, Inbred Strains
  • Sarcoma, Yoshida / immunology*

Substances

  • Antibodies, Neoplasm
  • Antigens, Neoplasm
  • oncofetal antigens